Physician profile
Michael Thomas Philbin
NPI 1962414912
$5,078.34
in general payments reported to CMS, 2019-2025
3 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what 79% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.21 · 2020: $49.07 · 2021: $27.06 · 2022: $52.04 · 2023: $955 · 2024: $2,540 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,874 · Food and Beverage: $5.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,874.17 |
| Food and Beverage | $5.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,879.96 | 2023-2025 | |
| Sientra, INC. | $107.80 | 2020-2022 | |
| Allergan, INC. | $90.58 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Philbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.